Reacta are commercialising the work of the world leaders in allergy diagnostics in order to significantly improve the diagnosis and management of food allergy. The company is generating significant revenues internationally and is working to expand into a new manufacturing facility.

Acceleris has advised the company from pre-revenue and has introduced multiple rounds of private funding as well as sitting on the board of directors

Patrick Molyneux